权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting abnormal immunomechanics in the glioblastoma microenvironment to improve therapeutic response

针对胶质母细胞瘤微环境中的异常免疫力学以改善治疗反应

基本信息

批准号：
10187229
负责人：
Meenal Datta
金额：
$ 19.11万
依托单位：
UNIVERSITY OF NOTRE DAME
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10187229
关键词：
3-Dimensional Adjuvant Bioinformatics Biological Biological Markers Biophysical Process Blood Blood Vessels Cell Compartmentation Cells Cephalic Data Enzyme-Linked Immunosorbent Assay Evaluation Excision Extracellular Matrix Feedback Fibrosis Flow Cytometry Genetic Genetic Models Glioblastoma Histology Hypoxia Immune Immunosuppression In Situ In Vitro Interruption Knockout Mice Losartan Malignant Neoplasms Maps Measurement Measures Mechanics Mediating Microglia Modeling Molecular Mus Myelogenous Myeloid Cells Neoplasms in Vascular Tissue Neurologic Dysfunctions Newly Diagnosed Operative Surgical Procedures Outcome Pathologic Pathology Patients Pharmaceutical Preparations Pharmacology Phenotype Production Quantitative Reverse Transcriptase PCR Radiation Regulation Reporter Research Resistance Role Slice Solid Solid Neoplasm Stress System Techniques Testing Training Tumor Immunity Tumor-associated macrophages Western Blotting Work angiogenesis base biomarker panel cell growth cell motility chemotherapy clinically translatable combinatorial confocal imaging drug efficacy fighting immune checkpoint blockade immune checkpoint blockers implantation improved in vivo insight intravital imaging mechanical force mouse model novel polarized cell resistance mechanism response response biomarker single cell sequencing standard of care targeted agent therapy outcome therapy resistant three dimensional cell culture tissue biomarkers translational approach treatment response tumor tumor microenvironment tumor progression

项目摘要

ABSTRACT Newly diagnosed glioblastoma (GBM) patients have a dismal survival of less than 2 years despite aggressive currently available treatments. Immune checkpoint blockade (ICB), which has revolutionized the treatment of other solid tumors, fails to enhance survival in the majority of GBM patients. The immunosuppressive, hypoxic, and extracellular matrix (ECM)-rich tumor microenvironment (TME) may be largely responsible for this poor response. One of the largest and most immunosuppressive components of the GBM TME is the myeloid cell compartment, consisting mainly of resident microglia and infiltrating tumor-associated macrophages (TAMs). These myeloid cells exist along a spectrum of phenotypes and functions ranging from pro-tumor (pro-fibrotic, angiogenic, and immunosuppressive) to anti-tumor (immune-supporting), and can dictate response to therapy. Furthermore, the GBM TME harbors “solid stress” – a mechanical force originating from cells and ECM – that can compress blood vessels, induce hypoxia and immunosuppression, and hinder anti-tumor immunity and drug efficacy. Here it is proposed that “immunomechanics” between pro-tumor myeloid cells and solid stress are reciprocally regulated in GBM, further promoting the abnormal TME and mediating resistance to ICB. This mechanopathological feedback loop will be evaluated by i) confirming the ability of myeloid cells to exert solid stress, and ii) the reciprocal ability of solid stress to promote pro-tumor myeloid cell phenotype and function (Aim 1). Next, this reciprocal regulation will be interrupted (genetically and pharmacologically) in murine GBM models to i) establish the causal roles of myeloid cells and solid stress in mediating immunosuppression in the TME, and ii) propose translatable ways to overcome them (Aim 2). Finally, myeloid targeting approaches will be combined with ICB to enhance therapeutic outcome, and both physical (solid stress) and biological biomarkers of treatment response will be identified (Aim 3). The results of the proposed work in this K22 application will: i) facilitate my transition to independence, ii) lay the groundwork for a successful R01 application within 3 years, and iii) revealing novel and targetable biophysical mechanisms underlying tumor progression and treatment resistance.

摘要